David Simpson
About David Simpson
David Simpson is the Senior Medical Director at BeiGene in the San Francisco Bay Area with extensive experience in haematology and clinical research.
Current Role at BeiGene
David Simpson is currently serving as the Senior Medical Director at BeiGene in the San Francisco Bay Area. He leverages his extensive experience in haematology and clinical research to contribute to the company's innovative cancer treatments and medical trials. This role allows him to oversee and guide medical practices and protocols within the organization.
Previous Experience in Haematology
David Simpson has a significant background in haematology, having worked as a Haematologist at multiple institutions. His previous roles include a one-year tenure at Harbour Cancer Centre in Auckland, New Zealand, from 2018 to 2019, and a long service at Auckland Haematology in Takapuna, Auckland, from 2004 to 2018. Additionally, he dedicated 19 years to the Waitematā District Health Board in Takapuna, from 2000 to 2019. These positions have cemented his expertise in the treatment of blood cancers.
Educational Background
David Simpson's educational journey in medicine began at the University of Auckland, where he completed his MBChB from 1981 to 1986. He furthered his qualifications by achieving Fellowship of the Royal Australasian College of Physicians (FRACP) and Fellowship of the Royal College of Pathologists Australasia (FRCPA) between 1991 and 1996. These qualifications underpin his extensive medical knowledge and practice.
Clinical Research and Publications
With over two decades of involvement in clinical research and trials, David Simpson has made significant contributions to the field of haematology. His research work is well-documented in several peer-reviewed medical journals. He focuses on advancing treatments and improving outcomes for blood cancer patients through rigorous clinical trials and studies.
Participation in Medical Conferences
David Simpson actively participates in international medical conferences and symposiums. His contributions to these events help him stay updated with the latest advancements in haematology and share his research findings and clinical insights with the global medical community. This engagement also facilitates collaborations and partnerships within the field.